Navigation Links
Bionovo to Present at the JMP Securities Healthcare Conference
Date:9/21/2010

EMERYVILLE, Calif., Sept. 21 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI, BNVID), a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced that Dr. Isaac Cohen, O.M.D., Chairman and Chief Executive Officer, will be presenting at the JMP Securities Healthcare Conference at 4:00 p.m. ET on Tuesday, September 28, 2010. The event will be held at the New York Palace hotel in New York City.

Interested parties can access a live audio webcast of the presentation by visiting http://bionovo.com/investors/events or at http://www.wsw.com/webcast/jmp11/bnvi/. A replay of this webcast will also be available for 90 days following the conference at http://bionovo.com/investors/events.

About Menerba

Menerba is an oral, botanical-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market, which have been shown to increase the risk for breast and uterine cancers. Clinical tests conducted thus far, following the specific guidance of the FDA, have indicated that Menerba is effective and safe.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI, BNVID". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo to Present at Cambria Capital Investor Meeting
2. Bionovo Receives Positive Guidance from FDA on Menerba®
3. Bionovo Announces Reverse Stock Split
4. Bionovo Announces Publication Describing Menerbas Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
6. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
7. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
8. Bionovo Announces 2009 Highlights and Year-End Financial Results
9. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
10. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
11. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
(Date:3/24/2017)... and GENEVA , March 24, 2017 ... Tuberculosis Day revitalizes efforts to develop sutezolid as effective ... World Tuberculosis Day, TB Alliance and the Medicines Patent ... development of sutezolid, an antibiotic drug candidate which demonstrated ... the development of sutezolid in combination with other TB ...
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... Boulder, CO (PRWEB) , ... March 23, 2017 , ... ... higher bar for entry into teacher preparation programs. The NCTQ report suggests, based on ... boosting entry requirements would significantly improve teacher quality in the U.S. It argues that ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):